SG45503A1 - Substituted quinoline-2-carboxyamides their preparation and their use as pharmaceuticals and intermediates - Google Patents
Substituted quinoline-2-carboxyamides their preparation and their use as pharmaceuticals and intermediatesInfo
- Publication number
- SG45503A1 SG45503A1 SG1996010735A SG1996010735A SG45503A1 SG 45503 A1 SG45503 A1 SG 45503A1 SG 1996010735 A SG1996010735 A SG 1996010735A SG 1996010735 A SG1996010735 A SG 1996010735A SG 45503 A1 SG45503 A1 SG 45503A1
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- opt
- alkoxy
- substd
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19536263A DE19536263A1 (de) | 1995-09-28 | 1995-09-28 | Substituierte Chinolin-2-carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19605170 | 1996-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG45503A1 true SG45503A1 (en) | 1998-01-16 |
Family
ID=26019051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996010735A SG45503A1 (en) | 1995-09-28 | 1996-09-27 | Substituted quinoline-2-carboxyamides their preparation and their use as pharmaceuticals and intermediates |
Country Status (20)
Country | Link |
---|---|
US (2) | US5726305A (es) |
EP (1) | EP0765871B1 (es) |
JP (1) | JPH09124606A (es) |
KR (1) | KR970061869A (es) |
CN (2) | CN1120157C (es) |
AT (1) | ATE263155T1 (es) |
AU (1) | AU728208B2 (es) |
CA (1) | CA2186717A1 (es) |
CZ (1) | CZ283396A3 (es) |
DE (1) | DE59610950D1 (es) |
ES (1) | ES2215184T3 (es) |
HU (1) | HUP9602685A3 (es) |
IL (2) | IL135495A (es) |
MX (1) | MX9604378A (es) |
MY (1) | MY133647A (es) |
NO (1) | NO308600B1 (es) |
NZ (1) | NZ299455A (es) |
PL (1) | PL316321A1 (es) |
SG (1) | SG45503A1 (es) |
SI (1) | SI9600287A (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19650215A1 (de) * | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US20020198145A1 (en) * | 1999-06-10 | 2002-12-26 | Cognetix, Inc. | MuO-conopeptides and their use as local anesthetics |
CA2432642A1 (en) * | 2000-12-21 | 2002-08-08 | Subhash P. Khanapure | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
US20040146964A1 (en) * | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
CN100522946C (zh) | 2001-12-06 | 2009-08-05 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) * | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
PT1644336E (pt) * | 2003-06-06 | 2011-04-21 | Fibrogen Inc | Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena |
US8614204B2 (en) * | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
WO2005034929A2 (en) * | 2003-10-10 | 2005-04-21 | Fibrogen, Inc. | Tissue remodeling and vascularization |
EP1893186A2 (en) * | 2005-06-06 | 2008-03-05 | Fibrogen, Inc. | Improved treatment for anemia using a hif-alpha stabilising agent |
WO2006138511A2 (en) | 2005-06-15 | 2006-12-28 | Fibrogen, Inc. | Use of hif 1alfa modulators for treatment of cancer |
WO2007025798A2 (en) | 2005-07-27 | 2007-03-08 | F. Hoffmann-La Roche Ag | 4-aryloxy quinoline derivatives as 5-ht6 modulators |
US7728130B2 (en) * | 2005-12-09 | 2010-06-01 | Amgen Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity |
JP5161793B2 (ja) * | 2006-01-27 | 2013-03-13 | フィブロジェン, インコーポレイテッド | 低酸素症誘導因子(hif)を安定化するシアノイソキノリン化合物 |
WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
US7745461B1 (en) | 2006-02-27 | 2010-06-29 | Alcon Research, Ltd. | Method of treating dry eye disorders |
ES2533765T3 (es) * | 2006-03-30 | 2015-04-15 | Lg Electronics Inc. | Un método y un aparato para descodificar/codificar una señal de video |
CN103497184A (zh) * | 2006-04-04 | 2014-01-08 | 菲布罗根有限公司 | 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物 |
EP4095127A1 (en) | 2006-06-26 | 2022-11-30 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
EP2111399A2 (en) * | 2006-12-18 | 2009-10-28 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
US8048892B2 (en) * | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
CA2683956C (en) * | 2007-04-18 | 2012-12-18 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
US7569726B2 (en) * | 2007-04-18 | 2009-08-04 | Amgen Inc. | Indanone derivatives that inhibit prolyl hydroxylase |
WO2008137084A2 (en) * | 2007-05-04 | 2008-11-13 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
ES2389063T3 (es) * | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
WO2009002533A1 (en) * | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
AU2009314155B2 (en) | 2008-11-14 | 2015-10-08 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
ES2575154T3 (es) * | 2009-12-17 | 2016-06-24 | Merck Sharp & Dohme Corp. | Moduladores alostéricos positivos del receptor M1 de quinolina amida |
DK2672823T3 (en) | 2011-02-07 | 2016-11-28 | Biogen Ma Inc | S1P-modulating agents |
NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
CN104470899B (zh) | 2012-03-09 | 2017-12-26 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 |
MY171483A (en) | 2012-07-16 | 2019-10-15 | Fibrogen Inc | Process for making isoquinoline compounds |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
ES2905898T3 (es) | 2012-07-16 | 2022-04-12 | Fibrogen Inc | Formas cristalinas de un inhibidor de prolil hidroxilasa |
SG11201500339XA (en) * | 2012-07-27 | 2015-02-27 | Biogen Ma Inc | Atx modulating agents |
RU2666144C2 (ru) | 2013-01-24 | 2018-09-06 | Фиброген, Инк. | Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты |
BR112015031027A2 (pt) | 2013-06-13 | 2017-08-29 | Akebia Therapeutics Inc | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única |
MX2021001169A (es) | 2013-11-15 | 2023-02-10 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. |
BR112017015852A2 (pt) | 2015-01-23 | 2018-03-27 | Akebia Therapeutics Inc | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 |
IL292262B2 (en) | 2015-04-01 | 2024-02-01 | Akebia Therapeutics Inc | Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid |
MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
CN113302175A (zh) | 2018-11-09 | 2021-08-24 | 维瓦斯治疗公司 | 双环化合物 |
CN114072207B (zh) | 2019-04-16 | 2024-03-29 | 维瓦斯治疗公司 | 双环化合物 |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4015255A1 (de) * | 1990-05-12 | 1991-11-14 | Hoechst Ag | Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
EP0541042A1 (de) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
DE4233124A1 (de) * | 1992-10-02 | 1994-04-07 | Hoechst Ag | Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DK122693D0 (da) * | 1993-10-29 | 1993-10-29 | Hempels Skibsfarve Fab J C | Marin struktur |
EP0650960B1 (de) * | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE59401924D1 (de) * | 1993-11-02 | 1997-04-10 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
NZ270267A (en) * | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
-
1996
- 1996-06-29 IL IL13549596A patent/IL135495A/en not_active IP Right Cessation
- 1996-07-03 US US08/675,155 patent/US5726305A/en not_active Expired - Lifetime
- 1996-07-03 US US08/675,208 patent/US5719164A/en not_active Expired - Lifetime
- 1996-09-20 EP EP96115110A patent/EP0765871B1/de not_active Expired - Lifetime
- 1996-09-20 AT AT96115110T patent/ATE263155T1/de not_active IP Right Cessation
- 1996-09-20 ES ES96115110T patent/ES2215184T3/es not_active Expired - Lifetime
- 1996-09-20 DE DE59610950T patent/DE59610950D1/de not_active Expired - Lifetime
- 1996-09-25 KR KR1019960042606A patent/KR970061869A/ko not_active Application Discontinuation
- 1996-09-26 NZ NZ299455A patent/NZ299455A/en unknown
- 1996-09-26 CZ CZ962833A patent/CZ283396A3/cs unknown
- 1996-09-26 CN CN96122806A patent/CN1120157C/zh not_active Expired - Lifetime
- 1996-09-26 AU AU65838/96A patent/AU728208B2/en not_active Ceased
- 1996-09-26 IL IL11930296A patent/IL119302A0/xx unknown
- 1996-09-27 SG SG1996010735A patent/SG45503A1/en unknown
- 1996-09-27 SI SI9600287A patent/SI9600287A/sl unknown
- 1996-09-27 MY MYPI96004023A patent/MY133647A/en unknown
- 1996-09-27 CA CA002186717A patent/CA2186717A1/en not_active Abandoned
- 1996-09-27 NO NO964093A patent/NO308600B1/no not_active IP Right Cessation
- 1996-09-27 MX MX9604378A patent/MX9604378A/es unknown
- 1996-09-27 HU HU9602685A patent/HUP9602685A3/hu unknown
- 1996-09-27 PL PL96316321A patent/PL316321A1/xx unknown
- 1996-09-30 JP JP8276901A patent/JPH09124606A/ja active Pending
-
2000
- 2000-06-14 CN CN00118801A patent/CN1282737A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
HUP9602685A2 (hu) | 1998-09-28 |
CA2186717A1 (en) | 1997-03-29 |
CN1282737A (zh) | 2001-02-07 |
JPH09124606A (ja) | 1997-05-13 |
NO308600B1 (no) | 2000-10-02 |
EP0765871A1 (de) | 1997-04-02 |
MX9604378A (es) | 1997-03-29 |
AU728208B2 (en) | 2001-01-04 |
HUP9602685A3 (en) | 2001-04-28 |
IL119302A0 (en) | 1996-12-05 |
US5726305A (en) | 1998-03-10 |
CN1154365A (zh) | 1997-07-16 |
CZ283396A3 (en) | 1997-04-16 |
EP0765871B1 (de) | 2004-03-31 |
KR970061869A (ko) | 1997-09-12 |
MY133647A (en) | 2007-11-30 |
NO964093L (no) | 1997-04-01 |
NO964093D0 (no) | 1996-09-27 |
DE59610950D1 (de) | 2004-05-06 |
IL135495A (en) | 2002-12-01 |
NZ299455A (en) | 1997-06-24 |
CN1120157C (zh) | 2003-09-03 |
ATE263155T1 (de) | 2004-04-15 |
AU6583896A (en) | 1997-04-10 |
HU9602685D0 (en) | 1996-11-28 |
PL316321A1 (en) | 1997-04-01 |
US5719164A (en) | 1998-02-17 |
SI9600287A (en) | 1997-04-30 |
ES2215184T3 (es) | 2004-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG45503A1 (en) | Substituted quinoline-2-carboxyamides their preparation and their use as pharmaceuticals and intermediates | |
HK1013998A1 (en) | Carbapenems containing a carboxy substituted phenyl group processes for their preparation intermediates and use as antibiotics | |
DE69429708D1 (de) | Galanthamin Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente | |
AU6684894A (en) | Bicyclic amide derivatives and their use as muscle relaxants | |
LTIP187A (lt) | 4,13-dioksabiciklo[8.2.1]tridekanono dariniai, jų gavimo būdas, tarpiniai produktai jiems gauti ir juos turinčios farmacinės kompozicijos | |
PH24782A (en) | Composition containing a penem or carbapenem antibiotic and the use of the same | |
HK1011976A1 (en) | Antimicrobial carbapenem derivatives their reparation and their therapeutic use | |
HUT34210A (en) | Process for producing new cepheme-carboxylic acid derivatives and pharmaceutical compositions containing them as active ingredients | |
AU3822793A (en) | Novel benzyl enol ethers and their use as crop protection agents | |
IL88921A0 (en) | Anti-psychotic pharmaceutical compositions containing a certain imidazobenzodiazepine | |
BR1100564A (pt) | Formas cristalinas de mono-hidrato do cloridrato de endo-2,3-dihidro-n-(8-metil-8-azabiciclo[3.2.1]oct-3-il)-2 - -oxo-1h-benzimidazol-1-carboxamida e de mono-hidrato do cloridrato de endo-3-etil-2,3-di-hidro-n-(8-metil-8-azabiciclo[3.2.1]oc t-3-il)-2-oxo-1h-benzimidazol-1-carboxamida como antagonistas do 5-ht | |
IL110273A0 (en) | Use of cephem derivatives as anti-metastatic agents |